Persevere Therapeutics

What Persevere Therapeutics does

Persevere Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Chesterbrook, Pennsylvania. The company was founded in 2025 and emerged from stealth on March 3, 2026, around a single core asset: misetionamide (GP-2250), a novel, first-in-class small-molecule oxathiazine derivative acquired from Geistlich Pharma AG and Panavance Therapeutics. Misetionamide is a dual inhibitor of the oncogenic transcription factors c-MYC and NFkB; through c-MYC it selectively disrupts cancer-cell energy metabolism by reducing GAPDH and hexokinase activity and lowering ATP production, and through NFkB it suppresses cancer-cell proliferation and survival signaling. The drug is being positioned as a tumor-cell-selective agent with broad oncology applicability, demonstrated synergy with standard anti-cancer agents, and potential to enhance immunotherapy.

The company's lead clinical focus is the MIROC-1 Phase 1b/2a proof-of-concept trial in platinum-resistant ovarian cancer, a setting with significant unmet need and limited effective treatment options. A completed Phase 1 trial in 55-56 cancer patients showed an excellent safety profile and encouraging efficacy, and two INDs are open under the program. Secondary indications under exploration include pancreatic, melanoma, squamous-cell, breast, and colorectal cancers. Persevere is supported by 16 scientific publications on the asset and by an extensive patent estate.

The business model is pre-commercial and pre-revenue: Persevere generates no product sales today, and future revenue, if any, would derive from prescription oncology therapeutics sold post-approval via specialty pharmacy channels and oncology key-account relationships, with clinical development currently executed through research institutions and oncology treatment centers. The company is funded by an SEC Form D seed financing (first close of $1,574,999 against a $4,999,999 offering to 12 undisclosed investors) and operates with a small, fractional executive team including CEO Greg Bosch, CMO Seymour Fein, CCO Ben Steinmetz, and CFO Stanley Musial.

Name

Persevere Therapeutics

Legal name

Persevere Therapeutics, Inc.

Website

https://perseveretherapeutics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Persevere Therapeutics is a clinical-stage, privately held oncology company developing misetionamide (GP-2250), a first-in-class dual c-MYC/NFkB small-molecule inhibitor for platinum-resistant ovarian cancer and other solid tumors, currently advancing into a Phase 1b/2a proof-of-concept trial.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

Keywords

• Oncology therapeutics
• Small molecule drugs
• Clinical-stage biotech
• Cancer metabolism inhibitors
• Ovarian cancer treatment

Headquarters

HQ city

Berwyn

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Product Revenue: Persevere Therapeutics is a clinical-stage oncology company with no current revenue. The company is developing misetionamide for the treatment of platinum-resistant ovarian cancer and other cancers. Upon regulatory approval, revenue would be generated through the sale of prescription oncology therapeutics, likely distributed through specialty pharmacy channels.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Persevere Therapeutics is a clinical-stage oncology biopharmaceutical company developing misetionamide (GP-2250), a first-in-class small molecule that simultaneously inhibits the c-MYC and NFkB oncogenic transcription factors. Its lead program is being advanced through a Phase 1b/2a proof-of-concept trial (MIROC-1) for platinum-resistant ovarian cancer, with potential expansion into pancreatic, melanoma, squamous cell, breast, and colorectal cancers.

Product overview

Persevere Therapeutics is a clinical-stage oncology company with a single core product focus: misetionamide (GP-2250). Misetionamide is a novel small molecule therapeutic with a dual mechanism of action as a first-in-class dual inhibitor of c-MYC and NFkB oncogenic transcription factors. The drug candidate works by selectively disrupting cancer cell energy metabolism and inhibiting cancer cell proliferation and survival. The company is advancing misetionamide through clinical development, currently preparing for a Phase 1b/2a trial in platinum-resistant ovarian cancer, with potential applications across multiple cancer types including pancreatic, melanoma, squamous cell, breast, and colorectal cancers.

Differentiator

Problem solved

Functional benefit

Products and services

• Misetionamide (GP-2250) A first-in-class small molecule therapeutic that simultaneously inhibits the c-MYC and NFkB oncogenic transcription factors, selectively disrupting cancer cell energy metabolism (by reducing GAPDH and hexokinase and lowering ATP) and suppressing NFkB-driven proliferation and survival signaling. Being developed for cancer patients with platinum-resistant ovarian cancer and other solid tumors including pancreatic, melanoma, squamous cell, breast, and colorectal cancers.

Quantifiable outcome

• Phase 1 trial demonstrated excellent safety profile and encouraging efficacy in 56 treated cancer patients
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Geistlich Pharma AGcoreOEM/ Whitelabel/ Licensing Partner · 3 March 2026Persevere Therapeutics acquired the clinical-stage program and related assets for misetionamide (GP-2250) from Geistlich Pharma AG as part of its company launch. This acquisition transferred all intellectual property and development program rights for the misetionamide compound to Persevere Therapeutics, enabling the company to advance the drug into Phase 1b/2a clinical trials.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/perseveretx
• Xx.com/panavance

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Persevere Therapeutics